New Study Findings Underscore Importance of Physician/Patient Communication on Insulin Adherence and Outcomes

INDIANAPOLIS, June 11, 2016 /PRNewswire/ -- New data from a study funded by Eli Lilly and Company (NYSE: LLY) show that how healthcare professionals and people with diabetes communicate - as well as the perceived quality of the personal relationship between the parties - directly impacts knowledge of the disease by patients, distress related to living with diabetes, important care activities, such as frequency of self-monitoring blood glucose, and insulin adherence. Six abstracts from the Multinational Observational Insulin Progression (MOSA1c) study, which was led by Harvard-affiliated Brigham and Women's Hospital, are being presented at the 76^th American Diabetes Association Scientific Sessions in New Orleans.

"We know from many studies that the majority of patients with type 2 diabetes using insulin are not achieving glycemic control," said Seoyoung C. Kim, M.D., associate physician at Brigham and Women's Hospital, assistant professor of medicine at Harvard Medical School and lead investigator. "While the data from MOSA1c confirms these findings, more concerning is that despite less than one-third of patients achieving glycemic control in this two-year observational study, only about 40 percent of patients with sub-optimal control added additional diabetes medication. In addition, because the relationship between patients and healthcare professionals may have an effect on the amount of distress patients feel and, in some cases, the level of A1C, we recognize that how we communicate to patients and how patients receive that communication really matters."

Data from over 4,200 patients in 18 countries were monitored in a non-interventional manner for two years across North and Latin America, Europe, Asia, and the Middle East. Other findings included:

• Improvement in the patient-healthcare provider relationship was associated with a lower level of diabetes-related distress, higher diabetes knowledge scores, positive attitudes towards self-care, such as frequency of self-monitoring blood glucose, and higher self-reported adherence to the prescribed treatment.¹
• Patients who were younger, more highly educated and living in Asia were found to be more likely to have their insulin therapy progressed.²
• Younger age, higher baseline A1C level and use of NPH insulin were significantly associated with a higher A1C level at the end of the study, adjusted for adherence.³

"MOSA1c provides a broad view of clinical, psychosocial and health system factors available and will serve to create a greater understanding of needs within each system," said David Kendall, vice president, Global Medical Affairs, Lilly Diabetes. "These data can help us better understand why so many patients using insulin are not achieving glycemic goals. We know that this is a complex multi-factorial issue and it is critical to take into account the specific cultural, social and individual barriers people with diabetes face when adjustment of insulin therapy is considered most useful."

The results are an important step forward in helping the diabetes community understand insulin progression to help healthcare providers determine the right therapies at the right times for each patient. Given the complexities of available therapies across the globe, this should be an increasing area of research focus to help address this overwhelming public health issue. As a result of these findings, Lilly will be reaching out to diabetes experts from all regions included in the study in the coming months in order to gain a broad cross-cultural perspective on how best to explore the wealth of information from MOSA1c.

About MOSA1c
MOSA1c is a large, comprehensive study which examined associations between patients' backgrounds/behaviors, healthcare settings, healthcare provider relationships and treatment outcomes for type 2 diabetes in a long-term prospective manner and followed more than 4,000 adults and 220 healthcare providers in 18 countries around the world. More than half of the people studied were in emerging markets, where the need is great and data has been limited. Ages ranged from 20-79 (50 percent male) with a wide range of socioeconomic status, including education levels, employment and insurance type. The study not only provides breadth that helps reveal patterns of treatment on a global scale, but also depth into the lives of the participants that can make the data truly meaningful.

About Diabetes
Approximately 29 million Americans⁴ and an estimated 415 million people worldwide have type 1 and type 2 diabetes.⁵ Type 2 diabetes is the most common type, accounting for an estimated 90 to 95 percent of all diabetes cases.  Diabetes is a chronic disease that occurs when the body does not either properly produce or use the hormone insulin.⁴

About Lilly Diabetes
Lilly has been a global leader in diabetes care since 1923, when we introduced the world's first commercial insulin. Today we are building upon this heritage by working to meet the diverse needs of people with diabetes and those who care for them. Through research and collaboration, a broad and growing product portfolio and a continued determination to provide real solutions—from medicines to support programs and more—we strive to make life better for all those affected by diabetes around the world. For more information, visit www.lillydiabetes.com or follow us on Twitter: @LillyDiabetes.

About Eli Lilly and Company
Lilly is a global healthcare leader that unites caring with discovery to make life better for people around the world. We were founded more than a century ago by a man committed to creating high-quality medicines that meet real needs, and today we remain true to that mission in all our work. Across the globe, Lilly employees work to discover and bring life-changing medicines to those who need them, improve the understanding and management of disease, and give back to communities through philanthropy and volunteerism. To learn more about Lilly, please visit us at www.lilly.com and newsroom.lilly.com/social-channels.

P-LLY

References

¹ Linetsky B, Curtis BH, Rogers JR et al. The effect of the patient-physician relationship on insulin progression, diabetes distress and HbA1c control over time: Insights from the MOSA1c study. Data presented at the 76^th American Diabetes Association Scientific Sessions, New Orleans, LA.

² Kim SC, Eddings W, Rogers J et al. Effects of patient, physician and health care environment factors on insulin progression in patients with T2DM: the MOSA1c study. Data presented at the 76^th American Diabetes Association Scientific Sessions, New Orleans, LA.

³ He M, Curtis BH, Eddings W et al. Factors associated with insulin adherence among patients with type 2 diabetes: the MOSA1c study. Data presented at the 76^th American Diabetes Association Scientific Sessions, New Orleans, LA.

⁴ Centers for Disease Control and Prevention. National Diabetes Statistics Report, 2014. Available at: http://www.cdc.gov/diabetes/pubs/statsreport14/national-diabetes-report-web.pdf. October 2014.

⁵ International Diabetes Federation. IDF Diabetes Atlas, 7th edn. Brussels, Belgium: International Diabetes Federation, 2015. http://www.idf.org/diabetesatlas.

Refer to: Julie Williams, [email protected], 317-627-4056 

Photo - http://photos.prnewswire.com/prnh/20160609/377471-INFO
Logo - http://photos.prnewswire.com/prnh/20031219/LLYLOGO

SOURCE Eli Lilly and Company

Related Links

http://www.lilly.com